Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
6,016 total articles
EHang has moved from eye-catching demos to tangible commercial signals: Guinness-record drone operations, successful pilotless EH216-S flights in prime national events, a CTO appointment to drive industrialization, and encouraging sector growth forecasts. With a market cap near $692M and shares trading off 52-week highs, this trade targets a reboun…
American Public Education has a durable online education franchise, expanding nursing footprint, healthy free cash flow and a sub-$1.0B market cap. Fundamentals and a conservative valuation path support a long trade. We lay out entry, stop and target levels and a clear list of catalysts and risks.
Verisk has the data, clients, and cash flow to benefit from AI-driven automation without being disrupted. If AI becomes a productivity tool rather than a revenue destructor, the stock can re-rate from present multiples. This trade is a long position with a $174.23 entry, $160 stop, and $260 target over a long-term (180 trading days) horizon.
Alphatec (ATEC) plunged after a May earnings miss and disclosures about installation timing. The stock now trades at $8.12 with a market cap near $1.25B and a P/S of 1.58. Much of the 'slower growth' story looks baked into the price; this trade idea targets a rebound toward the $10.50 area while using a stop under the 52-week low to protect against…
Barclays (BCS) is a cheap, profitable global bank with a diversified footprint and a trailing P/E around 9.6 and PB below 1.0. We retain a buy stance and offer a tactical swing trade: entry $22.81, target $26.00, stop $21.00. The setup leans on valuation, steady volumes and dividend yield, but recent disclosures, legal probes, and elevated cyber/cr…
Clipper Realty is trading at an unusually low market cap relative to its operating scale and offers a double-digit implied yield once you annualize the recent quarterly distribution. Fundamentals are mixed—negative EPS and balance-sheet oddities—but cheap EV metrics, a recent run of solid NOI/FFO prints and a near-term ex-dividend date create a tac…
Elekta is a global med‑tech leader in radiotherapy hardware and oncology software. Current price action looks range-bound but the business has latent upside if order flow and software/service mix recover. This trade targets a rebound into the $9 area while keeping risk tight below $5.25.
PepsiCo's mix of scale, steady free cash flow ($8.84B), and an expanding healthier-premium snack portfolio makes it a pragmatic swing trade as the market prizes 'permissible snacking'. Valuation is reasonable (P/E ~23.3, EV/EBITDA ~14.0) and the stock yields ~3.8%. Trade plan: enter $151.50, stop $146.00, target $162.00 over ~45 trading days.
Tesla keeps refusing to collapse. Multiple durable demand drivers, improving services revenue and margin optionality make a tactical long reasonable today. This trade targets a measured move higher while respecting volatility through a disciplined stop.
Carter Bankshares (CARE) just checked a major box by resolving a non-performing loan tied to Justice Entities. With market cap near $581M, TTM EPS roughly $1.41 and a P/B around 1.38, the stock looks reasonably priced. This trade idea outlines an actionable long with entry, stop and target for a 45-trading-day horizon while weighing catalysts and r…
Hafnia is trading above key moving averages, offers a near-6% yield and sits on a market cap of roughly $4.41B. Technicals show recent strength, fundamentals show a profitable shipping operator, and corporate moves (TORM share sales) add optionality. This is a mid-term swing long idea: enter at $8.86, stop $8.00, target $10.50 (45 trading days).
Seagate shares have been slammed on headline volatility despite clear demand tailwinds from AI data centers. Fundamentals show strong cash generation, high margins, and constrained supply dynamics that justify a tactical long. This trade plan uses a disciplined entry at $703.10 with a $620 stop and $820 target over a mid-term 45 trading day horizon…
ImmunityBio (IBRX) just strengthened its bladder-cancer play with an exclusive U.S. deal for Tokyo-172 BCG and five U.S. patents for its ANKTIVA plus BCG platform through 2035. At a market cap near $7.76 billion and an enterprise value around $8.58 billion, the stock already prices in major success. The trade: a speculative long entry at $7.40 targ…
Lilly is no one-product story. With blockbuster GLP-1 cash flows supporting a deep pipeline (retatrutide, oral GLP-1 Foundayo) and meaningful free cash flow, LLY has the balance sheet and execution runway to push higher. This trade idea targets a measured long with a clear stop, leaning into continued momentum while respecting valuation.
PayPal trades at a mid-single-digit multiple of earnings with strong free cash flow, improving Venmo traction and a management reset underway. This is a tactical long: enter near $44.75, stop at $38.60, target $70 over a multi-month holding period. The trade profits if execution and margin stabilization follow through; it loses if competition and s…
Rocket Lab is executing — revenue growth, margin expansion and defense contracts are real. That said, the stock is trading at a sky-high multiple, momentum and hype around SpaceX are making the name crowded, and short-term upside appears priced in. This trade idea: a defined short with clear entry, stop and target over a mid-term (45 trading days) …
AppLovin (APP) is a rare adtech compounder showing large-scale revenue growth and exceptional profitability. With Q1 revenue of $1.84B (59% YoY), EBITDA margins expanding above 80%, and accelerating ad share gains versus larger peers, the company can justify a re-rating. This trade idea lays out an entry at $495.00, a stop at $420.00 and a long-ter…
Dutch Bros (BROS) reported strong comp growth and raised guidance, yet the stock slipped on elevated valuation. The business is expanding aggressively with attractive unit economics and healthy cash flow. We propose a tactical long: entry $53.40, stop $47.00, target $68.00, horizon 180 trading days. Risk is real — high P/E and macro pressure — but …
Oneok (OKE) trades at $93.90 and yields ~4.4% with a history of steady distributions and a recent beat-and-raise tone to guidance. With a reasonable 16.7x P/E, EV/EBITDA of 12.5 and $2.24B in free cash flow, this trade targets $112.70 over a long-term window (180 trading days) with a stop at $84.00. The risk profile is medium — interest-rate sensit…
Nu Holdings (NU) plunged after Q1 headlines focused on margins and near-term spending, but the business continues to grow rapidly — $5.32B revenue in Q1 and 135M customers. The selloff has pushed technicals into deep-oversold territory and trimmed valuation to a mid-teens P/E. This is a tactical long for traders willing to accept execution and macr…
Nebius (NBIS) delivered spectacular top-line growth in Q1 2026, but the stock now carries a premium that leaves little room for execution or macro disappointment. For traders worried about rate volatility, margin normalization or contract slippage, a short on NBIS around $199.85 with a $150 target (mid-term) is a tactical way to express a view that…
Berkshire Hathaway trades at roughly $1.05 trillion market cap with a P/E near 15, a rock-solid balance sheet and a $397.4 billion cash war chest. With new CEO Greg Abel accelerating buybacks and reallocating capital into high-conviction positions like Alphabet, the company can generate shareholder returns even without Warren Buffett at the helm. T…
Mammoth Energy Services (TUSK) trades like a deeply discounted oilfield-services operator. Market cap sits near $153M while enterprise value is roughly $61M, signaling meaningful net cash or asset value relative to equity. With a P/B around 0.58 and a forward-ish P/E near mid-teens, the stock looks cheap versus replacement-value logic. This trade i…
Topicus has been punished by investor impatience after a string of integration and growth hiccups. We view the current setup as a tactical long: the business still owns durable vertical SaaS assets, free-cash-generation potential and visible margin leverage. This trade pairs a disciplined entry with a tight stop and a clear target to capture a mult…
Pacira (PCRX) remains a viable tactical long. Exparel's growing real-world evidence for cost savings and continued revenue beats, combined with a roughly 15% free cash flow yield and modest valuation metrics (P/S ~1.2, EV/EBITDA ~9.6), support a mid-term rebound. I lay out an entry, stop and target for a mid-term trade and the key catalysts and ris…
